Dr Bram Verstockt (University Hospital Leuven, Belgium) presented the results of this multi-omic data integration with network analysis. He explained that the molecular mechanisms which orchestrate the heterogeneity of CD are poorly understood.
In a discovery cohort of 98 CD patients, 576 unique proteins were measured in blood. All patients were also genotyped. The 2 resulting datasets were then integrated using an innovative algorithm called Multi-Omics Factor Analysis (MOFA). From this analysis, 5 so-called latent factors (LFs: representative variables capturing the sources of variation in omic datasets) associated with at least 1 clinical phenotype were identified. Clustering patients along LFs achieved meaningful separation of clinical phenotypes like perianal penetrating disease.
The top-ranking proteins associated with perianal disease were involved in inflammatory pathways and autophagy, or were already known to be implicated in CD. Dr Verstockt: “Many of the genes encoding these proteins are significantly dysregulated in draining perianal fistula, as compared to paired rectal mucosa, in independent patients. The majority of the differentially expressed serum proteins (77.8%) could be validated in an independent cohort of 88 newly diagnosed CD patients”. Seven mutations mapped to transcription factors (SMAD3, BACH2) and post-translational regulators (such as IFNGR2, IL10, IL2RA, SLC2A4RG, and ZMIZ1) could potentially regulate perianal disease pathophysiology and could thus be considered novel drug targets. Dr Verstockt added that network analysis can also highlight potential repurposing of already existing drugs in other diseases.
In another study, an integrated multi-omics data analysis revealed microbiome-driven proteolysis as a contributing factor to the severity of ulcerative colitis (UC) disease activity. Certain members of the microbiome, such as Bacteroides vulgatus, may contribute to exacerbating disease activity in UC through protease activity. In vivo and in vitro experiments provide evidence that bacterial protease inhibition may be a novel therapeutic approach in UC [2].
A third multi-omics analysis revealed specific bio-geographical and functional characteristics in inflammatory bowel disease (IBD) intestinal mucosa. The results provide a unique and comprehensive cell map of IBD in a location-specific context, potentially shedding light upon unexplained clinical phenomena [3]. For example, an upregulated IL-6 pathway in Treg cells was recognised as sigmoid-specific in UC patients, which may help explain colonic perforations associated with anti-IL-6R treatment. The results may allow one to tailor therapies to affected areas to improve treatment efficacy.
- Sudhakar P, et al. ECCO-IBD 2020, OP15.
- Mills R, et al. ECCO-IBD 2020, OP31.
- Maimon N, et al. ECCO-IBD 2020, OP33.
Posted on
Table of Contents: ECCO 2020
Featured articles
Gut Microbiome as Treatment Target
Response to faecal microbiota transplantation in UC
Bioactives produced by gut bacteria to modulate immune response
Big Data Analysis
Multi-omics help describe CD phenotypes
The positive impact of genetic data on drug development
Experimental Therapies: Study Results
AMT-101: an oral human IL-10 fusion protein
Phase 2 results of first-in-class TL1A inhibitor
Open-label extension study of risankizumab: final results
Clinical remission after dose escalation of upadacitinib
Short- and Long-Term Treatment Results
Infliximab discontinuation increases relapse risk
Tofacitinib ‘real-world’ effectiveness in active UC
Subcutaneous ustekinumab as maintenance therapy in UC
Subcutaneous vedolizumab maintenance therapy in CD
Vedolizumab treatment persistence and safety
Specific Therapeutic Strategies
Impact of strategies on intestinal resection rate
Early ileocaecal resection in CD patients failing conventional treatment
Biologics before surgery in IBD do not elevate infection risk
Top-down infliximab superior to step-up in children with CD
High versus standard adalimumab in active UC
Head-to-Head Comparison of Treatments
Vedolizumab and anti-TNF therapies: a real-world comparison
Cancer Risk
Increased risk of small bowel cancer in IBD
Increased incidence of colorectal cancer and death in CD
Risk of rectal, anal cancer increased in perianal CD
Glyco-fingerprint as risk factor of UC-associated cancer
Miscellaneous Topics
Resolution of mucosal inflammation has dramatic effect
PICaSSO validated in real-life study
Re-inducing inflammation in organoids from UC patients
Role of immune cells in intestinal fibrosis
Association between meat consumption and IBD risk
CD exclusion diet corrects dysbiosis
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com